PDF(Pubmed)
Abstract：
This comprehensive review examines the efficacy, safety, and implications of intravitreal OZURDEX and intravitreal bevacizumab in treating diabetic macular edema (DME). DME is a common complication of diabetes mellitus and a leading cause of vision loss. OZURDEX, through sustained release of dexamethasone, targets inflammation and vascular permeability, while bevacizumab inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis. However, differences in safety profiles exist, with OZURDEX associated with an increased risk of intraocular pressure elevation and cataract formation and bevacizumab potentially carrying systemic risks. The choice between these treatments should be individualized, considering patient preferences, ocular and systemic comorbidities, and cost-effectiveness. Collaboration among healthcare providers is essential for the comprehensive management of DME. Future research should focus on long-term comparative studies, predictors of treatment response, and exploration of novel therapeutic targets to optimize treatment outcomes for patients with DME.
摘要：
这篇全面的综述检查了疗效，安全,以及玻璃体内OZURDEX和玻璃体内贝伐单抗治疗糖尿病性黄斑水肿（DME）的意义。DME是糖尿病的常见并发症和视力丧失的主要原因。Ozurdex,通过持续释放地塞米松，目标炎症和血管通透性，贝伐单抗抑制血管内皮生长因子（VEGF），减少血管生成。然而,安全概况存在差异，OZURDEX与眼压升高和白内障形成的风险增加相关,贝伐单抗可能带来系统性风险.这些治疗方法之间的选择应该是个性化的，考虑到患者的喜好，眼部和全身合并症，和成本效益。医疗保健提供者之间的合作对于DME的全面管理至关重要。未来的研究应该集中在长期的比较研究上，治疗反应的预测因子，并探索新的治疗靶点以优化DME患者的治疗效果。
